Abstract
The recent identification of the breast cancer-associated genes BRCA1 and BRCA2 is changing the clinical care provided to women at high-risk of breast cancer. We briefly review what is currently known about the clinical management of individuals who bear (or are suspected of bearing) genes mutations and which are the prevention strategies that would reduce the incidence and mortality of breast cancer in this subset of women.
MeSH terms
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / genetics
-
Breast Neoplasms / prevention & control*
-
Breast Neoplasms / surgery
-
Drug Therapy
-
Female
-
Genes, BRCA1
-
Genes, BRCA2
-
Genetic Testing
-
Heterozygote*
-
Humans
-
Mastectomy
-
Mutation
-
Ovarian Neoplasms / drug therapy
-
Ovarian Neoplasms / genetics
-
Ovarian Neoplasms / prevention & control*
-
Ovarian Neoplasms / surgery
-
Ovariectomy
-
Randomized Controlled Trials as Topic
-
Risk Reduction Behavior